Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer

Cancer Letters

Volumn 344, Issue 1, 2014, Pages 82-89

  Wang, Yi ^a   Cai, Yuepiao ^a   Ji, Jiansong ^b   Liu, Zhiguo ^a   Zhao, Chengguang ^a   Zhao, Yunjie ^a   Wei, Tao ^a   Shen, Xueqian ^a   Zhang, Xiuhua ^a   Li, Xiaokun ^a   Liang, Guang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

Author keywords

FGFR1; Irreversible FGFR1 inhibitors; Lung cancer; Non ATP competitive inhibition; Selectivity

Indexed keywords

A 114; A 117; ANTINEOPLASTIC AGENT; BISARYL 1,4 DIEN 3 ONE DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG CONFORMATION; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MOLECULAR DOCKING; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893710835     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.016     Document Type: Article

References (27)

1. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
2. Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem. J. 2011, 437:199-213.
3. Kumar S.B., Narasu L., Gundla R., Dayam R. A.R.P.S. J, Fibroblast growth factor receptor inhibitors. Curr. Pharm. Des. 2013, 19:687-701.
4. Lemieux S., Hadden M.K. Targeting the fibroblast growth factor receptors for the treatment of cancer. Anticancer Agents Med. Chem. 2012.
5. Norman R.A., Schott A.K., Andrews D.M., Breed J., Foote K.M., Garner A.P., Ogg D., Orme J.P., Pink J.H., Roberts K., Rudge D.A., Thomas A.P., Leach A.G. Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J. Med. Chem. 2012, 55:5003-5012.
6. Gavine P.R., Mooney L., Kilgour E., Thomas A.P., Al-Kadhimi K., Beck S., Rooney C., Coleman T., Baker D., Mellor M.J., Brooks A.N., Klinowska T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012, 72:2045-2056.
7. Guagnano V., Furet P., Spanka C., Bordas V., Le Douget M., Stamm C., Brueggen J., Jensen M.R., Schnell C., Schmid H., Wartmann M., Berghausen J., Drueckes P., Zimmerlin A., Bussiere D., Murray J., Graus Porta D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011, 54:7066-7083.
8. Liang G., Liu Z., Wu J., Cai Y., Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol. Sci. 2012, 33:531-541.
9. Fabbro D., Cowan-Jacob S.W., Mobitz H., Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol. Biol. 2012, 795:1-34.
10. Zhao C., Cai Y., He X., Li J., Zhang L., Wu J., Zhao Y., Yang S., Li X., Li W., Liang G. Synthesis and anti-inflammatory evaluation of novel mono-carbonyl analogues of curcumin in LPS-stimulated RAW 264.7 macrophages. Eur. J. Med. Chem. 2010, 45:5773-5780.
11. Liang G., Zhou H., Wang Y., Gurley E.C., Feng B., Chen L., Xiao J., Yang S., Li X. Inhibition of LPS-induced production of inflammatory factors in the macrophages by mono-carbonyl analogues of curcumin. J. Cell Mol. Med. 2009, 13:3370-3379.
12. Liang G., Li X., Chen L., Yang S., Wu X., Studer E., Gurley E., Hylemon P.B., Ye F., Li Y., Zhou H. Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg. Med. Chem. Lett. 2008, 18:1525-1529.
13. Wang Y., Xiao J., Zhou H., Yang S., Wu X., Jiang C., Zhao Y., Liang D., Li X., Liang G. A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. J. Med. Chem. 2011, 54:3768-3778.
14. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64:6652-6659.
15. Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J., Chen C.R., Chan T.C., France D.S., Ashwell M.A. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J. Biol. Chem. 2011, 286:20677-20687.
16. Kammasud N., Boonyarat C., Tsunoda S., Sakurai H., Saiki I., Grierson D.S., Vajragupta O. Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 2007, 17:4812-4818.
17. Zhang J., Zhang L., Su X., Li M., Xie L., Malchers F., Fan S., Yin X., Xu Y., Liu K., Dong Z., Zhu G., Qian Z., Tang L., Zhan P., Ji Q., Kilgour E., Smith P.D., Brooks A.N., Thomas R.K., Gavine P.R. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin. Cancer Res. 2012, 18:6658-6667.
18. Guagnano V., Kauffmann A., Wohrle S., Stamm C., Ito M., Barys L., Pornon A., Yao Y., Li F., Zhang Y., Chen Z., Wilson C.J., Bordas V., Le Douget M., Gaither L.A., Borawski J., Monahan J.E., Venkatesan K., Brummendorf T., Thomas D.M., Garcia-Echeverria C., Hofmann F., Sellers W.R., Graus-Porta D. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012, 2:1118-1133.
19. Chen Z., Wang X., Zhu W., Cao X., Tong L., Li H., Xie H., Xu Y., Tan S., Kuang D., Ding J., Qian X. Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. J. Med. Chem. 2011, 54:3732-3745.
20. Carmi C., Mor M., Petronini P.G., Alfieri R.R. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. 2012, 84:1388-1399.
21. Krejci P., Murakami S., Prochazkova J., Trantirek L., Chlebova K., Ouyang Z., Aklian A., Smutny J., Bryja V., Kozubik A., Wilcox W.R. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J. Biol. Chem. 2010, 285:20644-20653.
22. Nolen B., Taylor S., Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 2004, 15:661-675.
23. Johnson L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev. Biophys. 2009, 42:1-40.
24. Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W., DiNitto J.P., English J.M., Greig M.J., He Y.A., Jacques S.L., Lunney E.A., McTigue M., Molina D., Quenzer T., Wells P.A., Yu X., Zhang Y., Zou A., Emmett M.R., Marshall A.G., Zhang H.M., Demetri G.D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. USA 2009, 106:1542-1547.
25. Taylor S.S., Yang J., Wu J., Haste N.M., Radzio-Andzelm E., Anand G. PKA: a portrait of protein kinase dynamics. Biochim. Biophys. Acta 2004, 1697:259-269.
26. Zhou W., Hur W., McDermott U., Dutt A., Xian W., Ficarro S.B., Zhang J., Sharma S.V., Brugge J., Meyerson M., Settleman J., Gray N.S. A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol. 2010, 17:285-295.
27. Drilon A., Rekhtman N., Ladanyi M., Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 2012, 13:e418-426.